Table 2. Top gene ontology enrichment results for pfc mega module cadetblue.
Category | Name | p-value | q-value Bonferroni | Hit Count in Query List | Hit Count in Genome | Hit in Query List |
---|---|---|---|---|---|---|
GO: Biological Process | chromatin organization | 1.50E-09 | 4.12E-06 | 23 | 776 | SMYD1, ESR1, KAT6A, ASH1L, PAGR1, CBX4, KDM6B, ASH2L, MYSM1, PHF21A, BPTF, UBN1, CBX6, SUPT16H, SMARCD3, H3F3B, PAX5, PAX7, BRD1, CABIN1, MGEA5, NR1H4, CBX8 |
histone modification | 1.97E-06 | 5.40E-03 | 14 | 453 | SMYD1, KAT6A, ASH1L, PAGR1, KDM6B, ASH2L, MYSM1, PHF21A, PAX5, PAX7, BRD1, MGEA5, NR1H4, CBX8 | |
covalent chromatin modification | 2.87E-06 | 7.89E-03 | 14 | 468 | SMYD1, KAT6A, ASH1L, PAGR1, KDM6B, ASH2L, MYSM1, PHF21A, PAX5, PAX7, BRD1, MGEA5, NR1H4, CBX8 | |
chromatin remodeling | 1.47E-05 | 4.04E-02 | 8 | 165 | SMYD1, ESR1, ASH2L, MYSM1, BPTF, SMARCD3, H3F3B, PAX7 | |
RNA splicing | 1.60E-05 | 4.40E-02 | 12 | 403 | SRSF6, NUDT21, BCAS2, RBM39, RALY, RBM5, PRPF19, AKT2, CPSF2, SNRPD3, WDR77, AQR | |
protein alkylation | 2.44E-05 | 6.71E-02 | 8 | 177 | SMYD1, ASH1L, ASH2L, PAX5, PAX7, SNRPD3, WDR77, NR1H4 | |
protein methylation | 2.44E-05 | 6.71E-02 | 8 | 177 | SMYD1, ASH1L, ASH2L, PAX5, PAX7, SNRPD3, WDR77, NR1H4 | |
GO: Cellular Component | nucleoplasm part | 2.23E-05 | 7.49E-03 | 16 | 738 | MMS22L, SRSF6, NUDT21, KAT6A, PAGR1, CBX4, ELMSAN1, ASH2L, RBM39, PHF21A, UBN1, TONSL, PRPF19, SPOP, CPSF2, BRD1 |
chromosome | 1.21E-04 | 4.07E-02 | 17 | 943 | MMS22L, PSEN2, BCAS2, ESR1, KAT6A, ASH1L, ZNF207, ASH2L, ESCO2, CBX6, TONSL, SUPT16H, PRPF19, SMARCD3, H3F3B, NR1H4, CBX8 | |
ribonucleoside-diphosphate reductase complex | 1.24E-04 | 4.17E-02 | 2 | 3 | RRM2B, RRM2 | |
DNA replication factor A complex | 1.39E-04 | 4.67E-02 | 3 | 16 | BCAS2, TONSL, PRPF19 | |
nuclear replication fork | 1.40E-04 | 4.71E-02 | 4 | 41 | MMS22L, BCAS2, TONSL, PRPF19 | |
catalytic step 2 spliceosome | 2.96E-04 | 9.94E-02 | 5 | 90 | BCAS2, RALY, PRPF19, SNRPD3, AQR | |
GO: Molecular Function | oxidoreductase activity, acting on CH or CH2 groups | 3.32E-05 | 1.62E-02 | 3 | 10 | CYP2C8, RRM2B, RRM2 |
oxidoreductase activity, acting on CH or CH2 groups, disulfide as acceptor | 1.31E-04 | 6.38E-02 | 2 | 3 | RRM2B, RRM2 | |
ribonucleoside-diphosphate reductase activity, thioredoxin disulfide as acceptor | 1.31E-04 | 6.38E-02 | 2 | 3 | RRM2B, RRM2 | |
ribonucleoside-diphosphate reductase activity | 1.31E-04 | 6.38E-02 | 2 | 3 | RRM2B, RRM2 | |
chromatin binding | 1.69E-04 | 8.24E-02 | 12 | 516 | ESR1, KAT6A, ASH1L, RELB, CBX4, KDM6B, ASH2L, PHF21A, TLE4, SMARCD3, H3F3B, CABIN1 | |
Mouse Phenotype | increased immunoglobulin level | 1.16E-06 | 2.92E-03 | 14 | 307 | TRAF3IP2, GADD45B, SEMA4B, PSEN2, ESR1, SPTA1, ASH1L, BIRC3, RELB, MYSM1, CD4, PIK3C2A, RABGEF1, CABIN1 |
abnormal humoral immune response | 5.52E-06 | 1.39E-02 | 18 | 566 | TRAF3IP2, GADD45B, SEMA4B, PSEN2, ESR1, SPTA1, MAP3K14, ASH1L, BIRC3, RELB, TNFRSF11A, MYSM1, CD4, PIK3C2A, CD38, RABGEF1, PAX5, CABIN1 | |
abnormal immunoglobulin level | 7.68E-06 | 1.93E-02 | 17 | 522 | TRAF3IP2, GADD45B, SEMA4B, PSEN2, ESR1, SPTA1, MAP3K14, ASH1L, BIRC3, RELB, TNFRSF11A, MYSM1, CD4, PIK3C2A, RABGEF1, PAX5, CABIN1 | |
increased IgG level | 9.35E-06 | 2.35E-02 | 11 | 225 | TRAF3IP2, GADD45B, SEMA4B, ESR1, SPTA1, ASH1L, BIRC3, MYSM1, CD4, PIK3C2A, CABIN1 | |
cortical renal glomerulopathies | 1.18E-05 | 2.96E-02 | 10 | 188 | TRAF3IP2, GADD45B, PSEN2, MYO1E, ESR1, SPTA1, RRM2B, ASH1L, RELB, PIK3C2A | |
abnormal lymph node morphology | 1.85E-05 | 4.66E-02 | 14 | 390 | SELL, TRAF3IP2, TRAF1, PSEN2, ESR1, SPTA1, RRM2B, MAP3K14, BIRC3, RELB, TNFRSF11A, CD4, PIK3C2A, PIP | |
glomerulonephritis | 1.95E-05 | 4.91E-02 | 8 | 121 | TRAF3IP2, GADD45B, PSEN2, ESR1, SPTA1, ASH1L, RELB, PIK3C2A | |
abnormal B cell physiology | 3.21E-05 | 8.07E-02 | 18 | 644 | MYO1G, TRAF3IP2, GADD45B, SEMA4B, PSEN2, ESR1, SPTA1, MAP3K14, ASH1L, BIRC3, RELB, TNFRSF11A, MYSM1, CD4, PIK3C2A, RABGEF1, PAX5, CABIN1 | |
Pathway | Signaling by Wnt | 2.78E-06 | 2.47E-03 | 13 | 340 | LGR4, ASH2L, FZD4, ARRB2, ZNRF3, TLE4, VPS35, H3F3B, AKT2, GNAO1, FZD2, MOV10, RAC3 |
NF-kappa B signaling pathway | 1.07E-04 | 9.44E-02 | 6 | 95 | GADD45B, TRAF1, MAP3K14, BIRC3, RELB, TNFRSF11A | |
Apoptosis | 1.13E-04 | 9.97E-02 | 7 | 138 | GADD45B, TRAF1, SEPT4, SPTA1, MAP3K14, BIRC3, AKT2 |
Functional enrichment results from ToppFun for Prefrontal Cortex Mega Module Cadetblue, where Bonferroni-corrected p<0.1.